Sign up to save your podcasts
Or
Share A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC.
View all episodes
By H. Jack West, MDDr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC.